Sean McCutcheon

“And speaking to earlier line, with the Ibertamide Paducle coming up in about a week on the MRD negativity results, how does this inform your calculus on potential refiling on MRD for CART2-6 and accelerating the time to market for CERVIC-D in the frontline transplant as an eligible population.”

“On OPC1, can you speak to the requisite safety waiting period and challenges identifying and getting patients into the dose study? You know, what are your expectations for cadence of new patients enrolled and being treated moving forward now that the second patient's been dosed, that they were dosed about 90 days ago?”

“Ellie and thank you for taking our questions so for RGX 314 what is your latest perspective on the commercial outlook in the evolving landscape and in terms of launch preparation could you characterize your site qualification efforts so far and provide any color on which commercial sites you plan to qualify initially.”

“First, could you maybe go into some of your efforts to expedite the BLA filing once the Eclipse suite of studies is in hand? And then second question, you go into the rationale for starting a derelutamide combo in the hormone-sensitive setting as opposed to a combination with enzolutavide.”

“Could you speak to the trajectory of lesion reductions in those patients that were dose reduced? And then any commentary, and as much as you have this degree of granularity, on the composition of lesions for patients in the study, you know, fatty, fibrotic, and any commentary on robustness of response data to that?”